Trial Profile

A Phase I, Multicenter, Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-A83 in Patients With Advanced Malignant Neoplasm

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HMPL A83 (Primary)
Indications Acute myeloid leukaemia; Lymphoma; Myelodysplastic syndromes; Solid tumours
Focus Adverse reactions; First in man
Sponsors HUTCHMED

27 Nov 2025 According to HUTCHMED media release, data from the trial will be presented at the European Society for Medical Oncology (ESMO) Asia Congress 2025, taking place on December 5-7, 2025 in Singapore, and the American Society of Hematology (ASH) Annual Meeting taking place on December 6-9, 2025 in Orlando, USA.
18 Jun 2025 Status changed from recruiting to completed.
05 Mar 2024 Planned primary completion date changed from 1 Feb 2024 to 7 Jun 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com